Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 280

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 280
---
th Clinical Trials on Alzheimer’s
Disease (CTAD), 2022, San Francisco, CA, poster presentation)

CHARACTERIZING HETEROGENEOUS GROUPS
OF PATIENTS WITH MCI, PRE-MCI, AND DEMENTIA

In this study, CogniMIR miRNA
biomarkers were analyzed in plasma samples of 200 study participants with the following clinical diagnoses at the time of blood draw:
76 cognitively unimpaired (CU), 85 MCI, and 39 AD. The plasma samples were collected at the Penn Alzheimer’s Disease Research Center
(ADRC). Based on amyloid status (Aβ+/-), APOE genotype (APOE4 +/-), and sex, each sample was assigned to a specific subgroup. miRNA
pairs and classifiers effectively differentiated defined subgroups. In line with DiamiR’s results in other studies, sex-stratified
analysis yielded higher AUC values for females and males as compared to the combined group. The data supports the development of CogniMIR
miRNA biomarkers for better characterization of MCI/AD patients and understanding of AD-associated processes. Further, combining CogniMIR
miRNAs with other factors, such as amyloid and APOE, may enhance a biomarker algorithm.

| Separation of different subgroups using one pair, two pairs and three pairs of miRNAs. AUC: the area under the ROC curve. |

(Alzheimer’s Association International
Conference 2023, Amsterdam, Netherlands, poster presentation)

On June 19, 2024,
DiamiR announced acceptance of its abstract titled “Classifier algorithms to characterize various stages of Alzheimer’s disease
based on analysis of circulating brain-enriched and inflammation-associated microRNAs” for poster presentation at the 2024 International
Alzheimer’s Association Conference (AAIC) on July 29, 2024 (https://www.prnewswire.com/news-releases/diamir-biosciences-announces-poster-presentation-at-2024-alzheimers-association-international-conference-aaic-302176323.html).
On July 29, 2024, on behalf of DiamiR, Dr. Kumar reported the comparative analysis of 24 microRNAs comprising CogniMIR® panel in 200
plasma samples with DiamiR’s Generation 1 and Generation 2 software algorithms towards distinguishing cognitively unimpaired,